MTST (MetaStat) Total Receivables: $0.00 Mil (As of Feb. 2018)


What is MetaStat Total Receivables?

MetaStat MTST Total Receivables is $0.00 Mil as of Feb. 2018.

MetaStat's Total Receivables for the quarter that ended in Feb. 2018 was $0.00 Mil.

MetaStat Total Receivables Historical Data

* Premium members only.

The historical data trend for MetaStat's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Total Receivables Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.00 0.13 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.02 0.00 0.00 0.00

MetaStat Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
MetaStat (MTST) has a Total Receivables of $0.00 Mil as of Feb. 2018. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on MetaStat and its competitors.
Is MetaStat's Total Receivables too high?
MetaStat's current Total Receivables is $0.00 Mil.
How does MetaStat's Total Receivables compare to OBMP and NSPX?
MetaStat's Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on MetaStat and its competitors. MetaStat's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For MetaStat (MTST), the current Total Receivables is $0.00 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.